NCT01297530View on ClinicalTrials.gov

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY87-2243 in Patients With Advanced Malignancies

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Neoplasms

Interventions

DRUG

BAY87-2243

Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.

Trial Locations (3)

79106

Freiburg im Breisgau

0424

Oslo

SM2 5PT

Sutton